In combination with dabrafenib for the treatment of pediatric patients with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. <1yr or <8kg: not established.

Our work on the gene and the structure of the BRAF protein underpinned the discovery of drugs that target BRAF such as vemurafenib and dabrafenib, which have been recommended for use on the NHS. Photo ...